1American Diabetes Association. Diabetes Statistics. Available at: jsp. Accessed November 11, 2007.

2Forbes JM, Soldatos G, Thomas MC. Below the radar: Advanced glycation end products that detour ''around the side.'' Is HbAlc not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev. 2005 Nov;26(4):123-134.

3Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care. 2005 0ct;28(10):2465-2471.

4Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004 Aug;104(8):1287-1291.

5Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997 Jun 10;94(12):6474-6479.

6Li SY, Liu Y, Sigmon VK, McCort A, Ren J. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab. 2005 Jul;7(4):448-454.

7Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA. 1997 Dec 9;94(25):13915-13920.

8Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001 Nov;27(5 Pt 1):535-542.

9Huebschmann AG, Regensteiner Jg, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care. 2006 Jun;29(6):1420-1432.

10Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: Potential therapeutic target for cardiovascular disease. Drugs. 2004;64(5):459-470.

11Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991 Feb;87(2): 432-438.

12Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003 Apr;162(4):1123-1137.

13Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2587-2593. Epub 2005 Oct 13.

14Ramakrishna V, Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2007 Oct 9;[Epub ahead of print].

15Rebolledo OR, Actis Dato SM. Postprandial hyperglycemia and hyperlipidemia-generated glycoxidative stress: its contribution to the pathogenesis of diabetes complications. Eur Rev Med Pharmacol Sci. 2005 Jul-Aug;9(4):191-208.

Morris BW, MacNeil S, Hardisty CA, Heller S, Burgin C, Gray TA. Chromium homeostasis in patients with type II (NIDDM) diabetes. J Trace Elem Med Biol. 1999;13(1-2):57-61.

"Anderson RA. Chromium, glucose tolerance and diabetes. J Am Coll Nutr. 1998;17:548-555.

18Sun Y, Ramirez J, Woski SA, Vincent JB. The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium pico-linate to LMWCr. J Biol Inorg Chem. 2000;5(1):129-136.

19Speetjens JK, Collins RA, Vincent JB, Woski SA. The nutritional supplement chromium(III) tris(pico-linate) cleaves DNA. Chem Res Toxicol. 1999 Jun;12(6):483-487.

20Trow LG, et al. Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes. Int J Vitam Nutr Res. 2000;70(1):14-18.

21Kozlovsky AS, Moser PB, Reiser S, Anderson RA. Effects of diets high in simple sugars on urinary chromium losses. Metabolism. 1986;35:515-518.

22Goldfine AB, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: In vivo and in vitro studies. Metabolism. 2000;49(3):400-410.

23Boden G, Chen X, Ruiz J, van Rossum GD, Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1996;45(9):1130-1135.

24Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95(6):2501-2509.

25Tas S, Sarandol E, Ayvalik SZ, Serdar Z, Dirican M. Vanadyl sulfate, taurine, and combined vanadyl sulfate and taurine treatments in diabetic rats: Effects on the oxidative and antioxidative systems. Arch Med Res. 2007 Apr;38(3):276-283. Epub 2007 Jan 22.

26Davis RE, Calder JS, Curnow DH. Serum pyridoxal and folate concentrations in diabetics. Pathology. 1976;8(2):151-156.

27McCann VJ, Davis RE. Serum pyridoxal concentrations in patients with diabetic neuropathy. Aust NZ J Med. 1978;8(3):259-261.

28Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes. 1999;104(4):311-316.

Coggeshall JC, Heggers JP, Robson MC, Baker H. Biotin status and plasma glucose in diabetics. Ann NY Acad Sci. 1985;447:389-392.

30Cleary JP, Vitamin B3 in the treatment of diabetes mellitus: Case reports and review of literature. J Nutr Med. 1990;1:217-225.

31Mandrup T, et al. Nicotinamide in the prevention of insulin dependent diabetes mellitus. Diabetes Metabol Rev. 1993;9:295-309.

32Chakravarthy BK, Gupta S, Gode KD. Functional beta cell regeneration in the islets of pancreas in alloxan induced diabetic rats by (-)-epicatechin. Life Sci. 1982;31(24):2693-2697.

33Indian Council of Medical Research (ICMR), Collaborating Centres, New Delhi [no authors listed]. Flexible dose open trial of Vijayasar in cases of newly diagnosed non-insulin-dependent diabetes mellitus. Indian J Med Res. 1998;108:24-29.

34Sharma RD, Roghurem TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type 1 diabetes. Eur J Clin Nutr. 1990;44(4):301-306.

35Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: A double blind placebo controlled study. J Assoc Physicians India. 2001 Nov;49:1057-1061.

36Hannan JM, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, Abdel-Wahab YH. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br J Nutr. 2007 Mar;97(3):514-521.

37Leatherdale BA, et al. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed). 1981;282(6279):1823-1824.

38Ahmad N, Hassan Mr, Halder H, Bennoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull. 1999 Apr;25(1):11-13.

39Ojewole JA, Adewole SO, Olayiwola G. Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats. Cardiovasc J S Afr. 2006 Sep-Oct;17(5):227-232.

40Fernandes NP, Lagishetty CV, Panda VS, Naik SR. An experimental evaluation of the anti-diabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complement Altern Med. 2007 Sep 24;7:29.

41Shanmugasundaram ER, et al. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol. 1990;30(3):281-294.

42Shanmugasundaram ER, et al. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol. 1990;30(3):295-300.

43Mang B, Wolters M, Schmitt B, Kelb K, Lichtinghagen R, Stichtenoth DO, Hahn A. Effects of a cinnamon extract on plasma glucose, HbA, and serum lipids in diabetes mellitus type 2. Eur J Clin Invest. 2006 May;36(5):340-344.

44Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003 Dec;26(12):3215-3218.

Hlebowicz J, Darwiche G, Bjorgell O, Almer LO. Effect of cinnamon on postprandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr. 2007 Jun;85(6):1552-1556.

46Atanasov AT, Tchorbanov B. Anti-platelet fraction from Galega officinalis L. inhibits plateletaggregation. J Med Food. 2002 Winter;5(4):229-234.

47Pundarikakshudu K, Patel JK, Bodar MS, Deans SG. Anti-bacterial activity of Galega officinalis L. (Goat's Rue). J Ethnopharmacol. 2001 Sep;77(1):111-112.

48Witters LA. The blooming of the French lilac. J Clin Invest. 2001 0ct;108(8):1105-1107.

49Jackson MC, Lenney JF. The distribution of carnosine and related dipeptides in rat and human tissues. Inflamm Res. 1996 Mar;45(3):132-135.

50Hipkiss AR. Would carnosine or a carnivorous diet help suppress aging and associated pathologies? Ann NY Acad Sci. 2006 May;1067:369-374.

51Stuerenburg HJ. The roles of carnosine in aging of skeletal muscle and in neuromuscular diseases. Biochemistry (Mosc). 2000 Jul;65(7):862-865.

52Guiotto A, Calderan A, Ruzza P, Borin G. Carnosine and carnosine-related antioxidants: A review. Curr Med Chem. 2005;12(20):2293-2315.

53Peterszegi G, Molinari J, Ravelojaona V, Robert L. Effect of advanced glycation end-products on cell proliferation and cell death. Pathol Biol (Paris). 2006 Sep;54(7):396-404. Epub 2006 Aug 21.

54Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens). 2006 0ct-Dec;5(4):251-258.

55Song KH, Lee WJ, Koh JM, Kim HS, Youn JY, Park HS, Koh EH, Kim MS, Youn JH, Lee KU, Park JY. alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Commun. 2005 Jan 7;326(1):197-202.

56Thirunavukkarasu V, Anitha Nandhini AT, Anuradha CV. Lipoic acid improves glucose utilization and prevents protein glycation and AGE formation. Pharmazie. 2005 0ct;60(10):772-775.

57Yi X, Maeda N. alpha-Lipoic acid prevents the increase in atherosclerosis induced by diabetes in apolipoprotein E-deficient mice fed high-fat=low-cholesterol diet. Diabetes. 2006 Aug;55(8):2238-2244.

58Tang J, Wingerchuk DM, Crum BA, Rubin DI, Demaerschalk BM. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007 May;13(3):164-167.

59Kojima M, Sun L, Hata I, Sakamoto Y, Sasaki H, Sasaki K. Efficacy of alpha-lipoic acid against diabetic cataract in rat. Jpn J Ophthalmol. 2007 Jan-Feb;51(1):10-13. Epub 2007 Feb 9.

60Salmeron J, et al. Dietary fiber, glycemic load, and risk of non-insulin dependent diabetes mellitus in women. JAMA. 1997;277(6):472-477.

61Saleron J, et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care. 1997;20(4): 545-550.

62Eibl NL, Schmack CJ, Kopp HP, et al. Hypomagnesemia in type II diabetes: Effect of a 3-month replacement therapy. Diabetes Care. 1996;18(2):188-192.

63Simpson HC, et al. A high carbohydrate leguminous fibre diet improves all aspects of diabetic control. Lancet. 1981;(8210):1-5.

64Brenner Bm, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652-659.

65Cohen D, Dodds R, Viberti G. Effect of protein restriction in insulin dependent diabetics at risk of nephropathy. Br Med J (Clin Res Ed). 1987;294(6575):795-798.

Pedersen MM, et al. Renal effects from limitation of high dietary protein in normoalbuminuric diabetic patients. Kidney Int. 1989;27(suppl.):S115-S121.

67Anderson JW, Blake JE, Turner J, Smith B. Effects of soy protein on renal function and proteinuria in patients with type 2 diabetes. Am J Clin Nutr. 1998;68(6 suppl.):1347S-1353S.

68American Diabetes Association. Complications of Diabetes in the United States. Available at: www Accessed November 11, 2007.

The Mediterranean Diet Meltdown

The Mediterranean Diet Meltdown

Looking To Lose Weight But Not Starve Yourself? Revealed! The Secret To Long Life And Good Health Is In The Foods We Eat. Download today To Discover The Reason Why The Mediterranean Diet Will Help You Have Great Health, Enjoy Life And Live Longer.

Get My Free Ebook

Post a comment